Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in ... and make sure their analysis is clear and in no way misleading or deceptive.

(Reuters) -Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed ...

Eli Lilly expects about $3.5 billion in revenue for its diabetes treatment Mounjaro and $1.9 billion for its obesity drug Zepbound. CEO Dave Ricks told CNBC that the company has "tons of supply ...

There is no oral version of tirzepatide sold in the world today, as it is administered only by injection (Zepbound® and Mounjaro®). Lexaria has completed other research with oral ...

BioSpace reported that Eli Lilly faces fierce competition from Novo Nordisk (NYSE:NVO)'s Wegovy and Ozempic, which has led to lower-than-expected demand for Eli Lilly's weight loss and diabetes ...

Zepbound is an injectable prescription medication ... Furthermore, up to 50% of participants no longer exhibited symptoms of OSA. The medication also promotes weight loss, with patients losing ...

I have no reason to believe that the Mag 7 names won ... Eli Lilly and Company’s (NYSE:LLY) Mounjaro and Zepbound drugs are proving effective in helping patients lose weight, attracting ...

The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug Zepbound for obstructive sleep apnea, reported Annika Kim ...

Another top 10 holding is Eli Lilly, the pharma giant behind the Mounjaro and Zepbound obesity drugs ... But there is no sign that Smith (pictured) is deviating from his normal course, which ...

"Ozempic is the only version among the weekly injectables — Ozempic, Wegovy, Zepbound and Mounjaro ... and Harvard Medical School. There are no established guidelines for microdosing ...